ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.9% | 98.6% | 97.7% | 98.0% | 98.0% | 97.9% | 98.3% | 98.4% | 98.7% | 99.0% | 36.0% | 99.3% | |
| 59.0% | 51.9% | 40.0% | 60.7% | 53.7% | 46.1% | 42.1% | 35.4% | 24.8% | 25.4% | 36.0% | 33.8% | |
| 59.0% | 51.9% | 40.0% | 60.7% | 53.7% | 46.1% | 42.1% | 35.4% | 24.8% | 25.4% | 36.0% | 33.8% | |
| 17.4% | 19.3% | 23.6% | 14.6% | 17.1% | 21.6% | 23.3% | 25.1% | 31.0% | 32.7% | 30.1% | 28.6% | |
| 19.5% | 23.2% | 31.9% | 19.6% | 24.0% | 25.5% | 27.5% | 30.7% | 33.0% | 39.0% | 22.6% | 22.5% | |
| 0.0% | 1.4% | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 258.5% | 285.3% | 321.1% | 178.9% | 197.7% | 217.9% | 213.1% | 231.5% | 224.9% | 224.0% | 164.8% | 166.6% | |
| 45.7% | 62.2% | 75.9% | 44.1% | 49.8% | 52.8% | 71.6% | 83.6% | 86.1% | 98.6% | 64.6% | 64.9% | |
| 10.0% | 17.1% | 17.7% | 12.3% | 0.8% | 0.9% | 16.7% | 17.7% | 35.7% | 41.8% | 19.7% | 17.8% | |
| 10.5% | 11.8% | 15.4% | 7.6% | 13.5% | 11.1% | 15.0% | 22.2% | 21.5% | 21.3% | 14.0% | 14.8% | |
| 111.1% | 118.0% | 127.1% | 70.2% | 74.5% | 83.7% | 69.1% | 73.5% | 70.1% | 68.3% | 53.5% | 54.1% | |
| -158.5% | -185.3% | -221.1% | -78.9% | -97.7% | -117.9% | -113.1% | -131.5% | -124.9% | -124.0% | -64.8% | -66.6% | |
| -618.7% | -674.6% | -752.8% | -398.9% | -440.0% | -502.9% | -465.7% | -506.6% | -476.6% | -463.0% | -348.5% | -356.5% | |
| 46.6% | 50.5% | 54.6% | 50.8% | 53.6% | 62.1% | 56.9% | 60.5% | 56.7% | 54.4% | 61.1% | 54.3% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.